Dihexa for Magnesium Deficiency Brain Fog: The 2025 Magnesium L-Threonate Trial, the NMDA-BDNF Mechanism & the UK Review

Magnesium has quietly become the supplement of the moment — and behind the glycinate-and-threonate hype is a real cognitive story. Magnesium is the body's fourth most abundant mineral, the physiological gatekeeper of the brain's NMDA glutamate receptor, and a cofactor in more than 300 enzyme reactions, including the ATP-dependent machinery of memory consolidation. Yet a substantial share of UK and Western adults fall short of the reference intake, and ordinary blood tests miss most of it. In 2025 a Frontiers in Nutrition randomised, double-blind, placebo-controlled trial found that magnesium L-threonate (Magtein®) improved working and episodic memory and sleep in healthy adults — building on the 2023 UK Biobank study that linked higher dietary magnesium to larger brain volumes and the foundational Slutsky 2010 Neuron work showing that raising brain magnesium increases synaptic density. Because magnesium feeds the very synaptic plasticity and BDNF signalling that Dihexa — a positive modulator of HGF/c-Met synaptogenesis — also targets, people increasingly ask whether a peptide belongs in the conversation. This 2026 UK review walks through the new trial data, the NMDA-magnesium-BDNF mechanism, the measurement problem, the forms that actually reach the brain, and where Dihexa really sits: behind a dietary review and a cheap correction, not in front of it.

Magnesium Deficiency and Brain Fog in 2026: Common, Overlooked and Often Fixable

Magnesium is the fourth most abundant mineral in the body and one of the busiest. It is a cofactor in more than 300 enzymatic reactions — including every step that makes and uses ATP, the cell's energy currency — and it is essential to nerve conduction, muscle function, blood-pressure regulation and the synthesis of DNA and proteins. In the brain specifically, magnesium has a job that no other mineral does: it sits inside the NMDA glutamate receptor as a voltage-dependent plug, controlling the calcium flow that underpins synaptic plasticity, learning and memory. When magnesium is plentiful that gate is properly regulated; when it is low the receptor can become over-excitable, a state linked to excitotoxic stress, neuroinflammation and impaired plasticity.

Despite being so important, magnesium is one of the most commonly under-consumed nutrients in the Western diet. Modern processing strips it from food, intensive farming has lowered the magnesium content of some crops, and diets heavy in refined carbohydrates and light on green vegetables, nuts, seeds, wholegrains and legumes leave many people short. UK National Diet and Nutrition Survey data have repeatedly shown a meaningful proportion of teenagers and adults — women and younger age groups especially — falling below the lower reference nutrient intake for magnesium. The NIH notes a similar picture across populations, with a large share of adults not meeting requirements from diet alone.

The symptoms people notice when magnesium runs low — fatigue, poor sleep, low mood, irritability, muscle cramps, and difficulty concentrating or thinking clearly — overlap heavily with what the public calls "brain fog". That overlap is exactly what makes magnesium a fashionable suspect, and also what makes it tricky: those same symptoms are produced by poor sleep, stress, alcohol, an underactive thyroid, and iron, B12 or vitamin D deficiency. So magnesium is best treated as one common, correctable item on a longer list — cheap to address through diet and, where needed, a modest supplement, and therefore worth dealing with before anything exotic is considered.

The patient-facing question echoes the one running through the other nutritional posts on this site — vitamin D deficiency, vitamin B12 deficiency and iron deficiency: "my brain fog has a plausible, documented nutritional cause — does something like Dihexa belong anywhere in the picture?" With magnesium, as with the others, the honest answer keeps coming back to a single fact: the shortfall is removable, and you can simply put the missing mineral back.

The 2025 Magnesium L-Threonate Trial: Why Magnesium Was Back in the Headlines

The piece of evidence that pushed magnesium and the brain back into the wellness conversation was a 2025 randomised, double-blind, placebo-controlled trial published in Frontiers in Nutrition. The researchers gave around 100 generally healthy adults aged roughly 18 to 45, all reporting unsatisfactory sleep, either 2 g a day of magnesium L-threonate (Magtein®) or a matched placebo for six weeks, and measured cognition, a composite "cognitive age" index, sleep quality and several physiological markers.

The headline result: the magnesium L-threonate group showed significant gains in working and episodic memory, faster reaction times, and improvements in sleep quality and daytime functioning compared with placebo. Because the form used — L-threonate — is the one shown to raise magnesium in the cerebrospinal fluid rather than just the blood, the authors framed the cognitive effect as consistent with genuinely increasing brain magnesium, not merely correcting a peripheral shortfall.

Two caveats matter as much as the finding. First, this is a single, modestly sized trial in a self-selected group with poor sleep, using a proprietary, patented form of magnesium; it needs replication in larger, independent samples, and improving sleep is itself a powerful route to clearer thinking that can confound a "cognitive" reading. Second, the participants were not characterised as magnesium-deficient, so the study speaks to supplementation in adults with sleep complaints rather than to reversing a documented deficiency. It strengthens the case that brain magnesium matters for memory; it does not show that a peptide can clear today's fog, and it sits alongside — not above — the older mechanistic and population evidence below.

Why Magnesium Deficiency Is So Easy to Miss: The Measurement Problem

One reason magnesium deficiency is under-recognised is that it is genuinely hard to measure. Only about 1% of the body's magnesium circulates in the blood; the rest is locked in bone and inside cells. The body defends serum magnesium tightly, pulling it from stores to keep blood levels steady, which means a person can have a depleted tissue reserve — so-called subclinical or chronic latent deficiency — while a routine serum magnesium test still reads "normal". A clearly low serum magnesium (hypomagnesaemia) is therefore a late, specific sign, not a sensitive screen.

This matters for anyone trying to work out whether magnesium is behind their fog. Unlike vitamin D or ferritin, where a single blood test gives a reasonably useful answer, magnesium status is better judged from the whole picture: dietary intake, alcohol use, gut health, medications and symptoms, with serum magnesium reserved for confirming overt deficiency or monitoring at-risk patients. In practice that makes the sensible response to suspected shortfall a dietary and lifestyle review plus a low-risk correction, rather than a hunt for an abnormal number.

It also means the bar for reaching past a simple correction is low in a particular way: because you cannot easily prove magnesium is or is not the culprit, the cheap, safe move — eat more magnesium-rich food, cut excess alcohol, and consider a modest supplement — is also the diagnostic move. If the fog lifts, you have your answer at minimal cost. An unlicensed peptide offers no such information and carries far more risk.

The NMDA-Magnesium-BDNF Mechanism: How Low Magnesium Reaches the Synapse

Why would a mineral best known for muscle cramps affect thinking at all? The mechanistic story is unusually direct. Magnesium physically occupies the pore of the NMDA receptor, the glutamate channel central to long-term potentiation — the cellular basis of learning. At rest, magnesium blocks the channel; when a synapse is sufficiently active, the block lifts and calcium flows in, strengthening the connection. Adequate magnesium keeps this system precise. When magnesium is low, NMDA signalling becomes dysregulated and more prone to excitotoxicity, and the orderly strengthening and pruning of synapses suffers.

The cleaner cognitive thread connects magnesium to synaptic density and plasticity. In the landmark Slutsky et al. Neuron study (2010), raising brain magnesium with magnesium-L-threonate increased the number of functional synapses in the hippocampus and enhanced learning, working memory and long-term memory in both young and aged rats. Later cellular work confirmed that L-threonate regulates structural and functional synapse density by modulating intraneuronal magnesium. Magnesium status is also tied to brain-derived neurotrophic factor (BDNF), the master regulator of plasticity: adequate magnesium supports BDNF-driven synaptic strengthening, while deficiency, stress and the inflammation that accompanies it tend to suppress it. A 2024 review ties magnesium's neuroprotection explicitly to dampened neuroinflammation and preserved cognition.

The takeaway is that low magnesium plausibly nudges the brain toward dysregulated NMDA signalling, reduced BDNF-supported plasticity and lower synaptic density — a soft, diffuse downgrade rather than a focal lesion, which fits the vague, generalised quality of brain fog. And it is precisely this synaptic-plasticity endpoint that links the discussion to Dihexa, which arrives at a similar destination by a different molecular road.

What the Treatment Evidence Actually Shows: Magtein, Brain Volume and the Mixed Picture

Here is where honesty matters, because the magnesium-and-cognition literature is stronger on mechanism and association than on hard clinical proof. The observational data are encouraging. The 2023 UK Biobank study by Alateeq, Walsh and Cherbuin (around 6,000 adults aged 40–73) found that higher dietary magnesium was associated with larger brain volumes and fewer white-matter lesions, with the effect estimated to be equivalent to a brain roughly a year younger by age 55 in the highest-intake group — and with notable differences between the sexes. Other cohort and meta-analytic work links magnesium-rich diets to lower rates of cognitive decline.

The interventional data are more limited but real. The foundational Slutsky 2010 animal work and the 2025 human Magtein trial both point in the same direction — raising brain magnesium can support memory — and a magnesium-L-threonate trial in people with dementia (NCT02210286) registered on ClinicalTrials.gov reflects the clinical interest. But the trials are small, several use a single proprietary form, sleep improvement frequently confounds the cognitive signal, and almost none enrol people with documented magnesium deficiency as the entry criterion.

The fair summary for 2026 is this: not being short of magnesium is clearly worth securing, and the brain-magnesium data are genuinely interesting; but no trial shows that magnesium rapidly and reliably clears established brain fog in a deficient person the way replacing severe B12 might, and the strongest cognitive effects come from a specific, patented form rather than from food magnesium. That is the realistic backdrop against which any unlicensed peptide has to justify itself — and it is demanding, because the cheap intervention (better diet, less alcohol, a modest supplement) already captures most of the plausible benefit at almost no risk.

Who Gets Magnesium Deficiency Brain Fog: The Risk Groups That Matter

Deficiency is not evenly distributed, and knowing the high-risk groups is half the diagnosis. The biggest driver is simply a magnesium-poor diet — low in green vegetables, nuts, seeds, wholegrains and legumes, high in refined and processed food. On top of that, several common situations actively deplete magnesium. Heavy or regular alcohol use increases urinary magnesium loss and is a classic cause of deficiency. Gastrointestinal conditions — coeliac disease, Crohn's, chronic diarrhoea and post-bariatric-surgery states — reduce absorption of a mineral taken up in the gut.

Type 2 diabetes and insulin resistance raise magnesium loss through the kidneys, which is one reason magnesium and diabetic brain fog are linked. Several widely used medications deplete magnesium, notably long-term proton-pump inhibitors (for reflux), thiazide and loop diuretics, and some chemotherapy agents. Older adults absorb less and excrete more. And magnesium status interacts tightly with the other drivers of fog covered on this site: it shapes the stress response and sleep, so it overlaps with anxiety and chronic stress and poor sleep; it is used in migraine prophylaxis; and it is frequently low in the fatigue syndromes such as ME/CFS, fibromyalgia and long COVID, where it is worth checking.

The clustering cuts two ways. It means magnesium is worth reviewing in anyone with persistent fog, because it is so often quietly low and so cheap to correct. It also means a magnesium shortfall rarely explains everything on its own — addressing it is necessary housekeeping, but the fog that remains usually has other, co-existing causes that also need attention.

Magnesium Forms: Why L-Threonate Is the One People Mean for the Brain

Walk into any health shop in 2026 and the magnesium shelf is bewildering, which is part of why the topic generates so much search traffic. The forms differ mainly in how well they are absorbed and where they act. Magnesium oxide is cheap and high in elemental magnesium but poorly absorbed, so much of it stays in the gut and acts as a laxative. Magnesium citrate and magnesium glycinate (bisglycinate) are well-absorbed everyday forms; glycinate is popular for sleep and calm because the glycine is itself mildly calming and it is gentle on the stomach. Magnesium L-threonate (Magtein®) is the form developed specifically to cross into the central nervous system and is the one studied for memory and cognition, because it raises cerebrospinal-fluid magnesium more effectively than the others.

For correcting a simple dietary shortfall, the distinction matters less than the marketing suggests: any well-absorbed form (glycinate, citrate) will restore body magnesium and is far cheaper than threonate. For the specific goal of raising brain magnesium for cognition, L-threonate is the evidence-backed choice — but the evidence base, as above, is still young. Whichever form, the NHS guidance holds: 400 mg or less a day of supplemental magnesium is unlikely to cause harm, and the most common side effect of taking too much is diarrhoea. Our stacking guide discusses where magnesium sits among the everyday foundations people optimise before considering anything experimental.

The BDNF-HGF-c-Met Chain: Where Dihexa Enters the Picture

Now the part readers come for. If low magnesium nudges the brain toward dysregulated NMDA signalling, weaker BDNF-supported plasticity and lower synaptic density, is there a mechanistic case for a compound that pushes plasticity back up by another route? On paper, yes — and that is the entire reason the question gets asked.

Dihexa (PNB-0408) is an orally active, blood-brain-barrier-penetrant peptide that acts as a positive modulator of hepatocyte growth factor (HGF) and its receptor c-Met. In preclinical work — most notably Benoist and colleagues (JPET, 2014) — activating HGF/c-Met drove synaptogenesis, the formation of new dendritic spines and functional synapses, and improved performance in cognitive tasks. The HGF/MET system is also unusual in that it supports cerebrovascular health and the blood-brain barrier, not just neurons. Our mechanism of action page details the PI-3K/AKT and ERK signalling involved, and Dihexa vs BDNF unpacks the much-repeated "ten million times more potent than BDNF" claim and what it does and does not mean.

The convergence is real: magnesium supports NMDA-dependent, BDNF-driven plasticity and synaptic density; HGF/c-Met drives synaptogenesis toward the same functional endpoint. But convergence on an endpoint is not equivalence of cause. In magnesium deficiency the upstream problem is a missing mineral with a defined, cheap replacement; restoring it lifts the plasticity support directly and addresses the muscular, cardiovascular and metabolic effects that no synaptic peptide touches. Dihexa does not raise magnesium, does not unblock the NMDA gate, and has never been tested in this setting. The mechanistic story is a reason to be curious, not a reason to substitute an unproven peptide for a mineral you can simply replace.

Replacement First: The Only Evidence-Based Step

For anyone whose brain fog comes with a plausible magnesium shortfall, the evidence-based path is well-trodden and cheap. The first move is food: magnesium-rich foods — spinach and other greens, pumpkin and chia seeds, almonds and cashews, wholegrains, beans, lentils and dark chocolate — restore intake and bring a package of other nutrients with them. Where diet alone is not enough, a modest, well-absorbed supplement (glycinate or citrate for general repletion, L-threonate if the specific goal is cognition) within the NHS's 400 mg supplemental ceiling is low-risk and inexpensive.

Equally important is finding why magnesium was low, because the cause may matter more than the number. Heavy alcohol use, a long-term proton-pump inhibitor, uncontrolled diabetes, or a malabsorptive gut condition such as coeliac disease each need their own attention. And because magnesium so often travels with other shortfalls and drivers, a sensible work-up for persistent fog also checks the obvious companions — vitamin D, B12, ferritin/iron and thyroid function — alongside the non-laboratory basics of cognition: sleep, mood, alcohol, activity and stress. None of that requires a research peptide, and all of it has a stronger evidence base than one.

When Brain Fog Persists Despite Magnesium

A common and frustrating scenario: the diet is better, the supplement has been running for weeks, and the fog has lifted only partly — or not at all. This is where the temptation to reach for something stronger is greatest, and where clear thinking pays off most. The first question is whether magnesium was ever really the main driver. Because shortfall is so prevalent and so hard to confirm, it is frequently a contributor rather than the cause; correcting it was worth doing, but the real engine of the fog may be poor sleep, an undertreated mood disorder, a thyroid problem, ongoing iron, B12 or vitamin D deficiency, or a condition such as long COVID, ME/CFS or menopause that needs its own management.

The second question is whether enough has been done elsewhere. Where magnesium was genuinely contributing, the benefit often comes as much through improved sleep and a calmer stress response as through any direct synaptic effect, and that takes consistency rather than a one-off dose. Optimising the everyday cognitive basics and treating the co-existing causes systematically is unglamorous but effective. Only after that thorough, conventional work-up does it make sense to read about experimental agents — and even then, as our research and studies page sets out, the honest status of Dihexa for any cognitive indication is "mechanistically interesting, clinically unproven."

Magnesium-Specific Risks of Dihexa Use

Beyond the general safety questions that apply to any unlicensed peptide, two issues are specific to the magnesium setting. The first is masking. Magnesium shortfall is one of the easiest contributors to fog to address, and doing so carries wider benefits for blood pressure, muscle function, sleep and metabolic health. A compound that produces a subjective lift while the shortfall goes uncorrected does real harm by delaying that simple correction and by papering over the underlying reason — heavy alcohol use, an unrecognised gut condition, or uncontrolled diabetes — that the deficiency was quietly flagging.

The second is the importance of not over-correcting. Some people who suspect magnesium is behind their fog respond by taking very large doses, which is its own hazard: excess supplemental magnesium commonly causes diarrhoea, cramping and nausea, and in people with impaired kidney function it can accumulate to genuinely dangerous levels (hypermagnesaemia), because the kidneys are the main route of excretion. Anyone with chronic kidney disease should not take magnesium supplements without medical advice. The right answer to "could it be my magnesium?" is a dietary review and a measured correction — not megadosing, and not a research chemical. Finally, the general c-Met / oncology caution that runs through all Dihexa discussion applies here as everywhere: chronically amplifying a growth-factor pathway is not something to undertake casually outside a trial.

The Fosgonimeton Parallel and the Limits of Mechanism

The most important cautionary tale for anyone reasoning from mechanism to benefit is fosgonimeton (ATH-1017), the closest clinical-stage relative of Dihexa. Fosgonimeton is a small-molecule positive modulator of the same HGF/MET system, developed by Athira Pharma and taken all the way into human Alzheimer's trials precisely because the synaptogenic, neurotrophic rationale looked so compelling. In 2024 its pivotal Phase 3 LIFT-AD trial missed its primary cognitive endpoint.

The lesson is not that HGF/c-Met is uninteresting — it plainly is interesting — but that an elegant mechanism, even one carried into rigorous, well-funded human trials, does not guarantee a clinical benefit. If the most advanced drug targeting this exact pathway could not beat placebo on cognition in its main indication, the prior for an unlicensed, never-trialled peptide producing reliable gains in magnesium deficiency brain fog should be set accordingly low. Mechanistic plausibility is a hypothesis, not a result — a point that applies just as much to the magnesium-L-threonate story, which is promising but still early.

Who Should Absolutely Not Consider Dihexa for Magnesium Brain Fog

Some situations make experimentation clearly inappropriate. Anyone who has not yet reviewed their diet, alcohol intake and medications should do that first — the answer may be more leafy greens, less alcohol, or a £-few supplement, not a peptide. Anyone with kidney disease must be especially careful even with magnesium itself, let alone an experimental compound. Anyone who is pregnant or breastfeeding should not use Dihexa under any circumstances; an unlicensed HGF/c-Met peptide has no safety data in pregnancy. Anyone with a personal or strong family history of cancer should weigh the c-Met / oncology caution very seriously, since c-Met is implicated in tumour growth and invasion. And anyone whose fog might reflect a serious untreated condition — significant depression, a thyroid disorder, uncontrolled diabetes, sleep apnoea, or early dementia — needs proper assessment, because masking those with a subjective lift is dangerous.

This is the same conclusion reached across the nutritional-deficiency reviews on this site: the more treatable and correctable the underlying cause, the weaker the argument for reaching past it toward an unproven compound. A magnesium shortfall is about as correctable and low-cost as causes of brain fog get.

What the Evidence Supports for Magnesium Brain Fog in 2026 — The Bottom Line

Pulling the threads together, the evidence-based approach in 2026 is straightforward and almost entirely unglamorous. Review your intake if you have persistent fog, and lean on magnesium-rich food first. Correct any shortfall with a modest, well-absorbed supplement within the NHS's 400 mg supplemental ceiling — L-threonate if the specific goal is cognition, glycinate or citrate for general repletion. Find the cause of any depletion — alcohol, a proton-pump inhibitor, diabetes, a gut condition. Check the companions — vitamin D, B12, iron and thyroid — because they cluster. And address the non-laboratory drivers of cognition: sleep, mood, alcohol, activity and stress, which between them explain a great deal of everyday brain fog.

What the evidence does not yet support is treating magnesium L-threonate as a proven cognitive drug, megadosing in pursuit of a sharper mind, or substituting an experimental peptide for a mineral you can replace for pennies. The 2025 Magtein trial and the UK Biobank brain-volume data make a genuinely interesting case that brain magnesium matters; they make no case at all for a research chemical. Dihexa remains, for magnesium deficiency as for every other indication on this site, a compound with an interesting mechanism and no human efficacy or safety data in the condition — behind the dietary review and the supplement, not in front of them. For the broader picture, see our cognitive enhancement overview and Dihexa vs other nootropics.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Alcohol Brain Fog & ARBD (2026) — heavy drinking depletes magnesium and compounds the fog.
• Dihexa for Vitamin D Deficiency Brain Fog (2026) — the companion deficiency that clusters with low magnesium.
• Dihexa for Vitamin B12 Deficiency Brain Fog (2026) — another testable nutritional cause of fog.
• Dihexa for Iron Deficiency & Anaemia Brain Fog (2026) — the third member of the nutritional-fog cluster.
• Dihexa, Sleep & Memory Consolidation (2026) — magnesium's biggest cognitive route runs through better sleep.
• Dihexa for Migraine & Chronic Migraine (2026) — magnesium is an established migraine-prevention option.
• Dihexa for Anxiety & Stress (2026) — magnesium, the stress response and the HPA axis.
• Dihexa for Diabetes Brain Fog (2026) — diabetes is a major cause of magnesium loss.
• Dihexa for Coeliac Disease & Gluten Brain Fog (2026) — malabsorption that depletes magnesium.
• The Dihexa Stacking Guide — where magnesium sits among the everyday foundations.
• Dihexa vs BDNF: What "10 Million Times More Potent" Actually Means — in-depth look at the BDNF mechanism claim.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines, cerebrovascular angiogenesis.
• Side Effects & Risks — the general safety picture.
• Fosgonimeton & Athira — the cautionary Phase 3 story.

External Authoritative Sources Cited

• The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial (Frontiers in Nutrition, 2025).
• Alateeq K, Walsh EI, Cherbuin N. (European Journal of Nutrition, 2023). Dietary magnesium intake is related to larger brain volumes and lower white matter lesions with notable sex differences (UK Biobank, n = 6,001).
• Slutsky I et al. (Neuron, 2010). Enhancement of learning and memory by elevating brain magnesium (magnesium-L-threonate, synaptic density).
• Neuroprotective effects of magnesium: implications for neuroinflammation and cognitive decline (review, 2024).
• Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia (ClinicalTrials.gov, NCT02210286).
• NIH Office of Dietary Supplements — Magnesium Health Professional Fact Sheet (NMDA, requirements, deficiency, prevalence).
• NHS — Vitamins and minerals (Others): magnesium reference nutrient intake (300 mg men / 270 mg women) and the 400 mg supplement upper level.
• HGF and MET in brain development and neurological disorders (Frontiers in Cell and Developmental Biology, 2021).
• Benoist CC et al. (JPET, 2014). Dihexa procognitive effects via HGF/Met.